Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence

Vascular Medicine. Authors: Alexandra Kilian, Marianne S. Clancy, Scott Olitsky, James R. Gossage and Marie E. Faughnan.

This article is available for public use and does not require purchase. Click to view the full article.